American Journal of Kidney Diseases
Volume 54, Issue 1 , Pages 104-111 , July 2009

β2-Microglobulin and Phosphate Clearances Using a Wearable Artificial Kidney: A Pilot Study

  • Victor Gura, MD

      Affiliations

    • Cedars Sinai Medical Center, UCLA, The David Geffen School of Medicine, Los Angeles, CA
    • Xcorporeal Inc, Los Angeles, CA
    • Corresponding Author InformationAddress correspondence to Victor Gura, MD, Associate Clinical Professor of Medicine. UCLA, The Geffen School of Medicine, 9100 Wilshire Blvd, Ste 360W, Beverly Hills, CA 90212
    • ,
  • Andrew Davenport, MD

      Affiliations

    • Center for Nephrology, Division of Medicine, Royal Free and University College Hospital Medical School, London, UK
    • ,
  • Masoud Beizai, PhD

      Affiliations

    • Xcorporeal Inc, Los Angeles, CA
    • ,
  • Carlos Ezon, MD

      Affiliations

    • Xcorporeal Inc, Los Angeles, CA
    • ,
  • Claudio Ronco, MD

      Affiliations

    • Divisione de Nefrologia, Ospedale San Bortolo, Vicenza, Italy

Received 14 November 2008 ,Accepted 4 February 2009.

References 

  1. Gotch FA, Sargent JA. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int. 1985;28:526–534
  2. Kalantar-Zadeh K, Kovesdy CP, Derose SF, Horwich TB, Fonarow GC. Racial and survival paradoxes in chronic kidney disease. Nat Clin Pract Nephrol. 2007;3:493–506
  3. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347:2010–2019
  4. Spalding EM, Chandna SM, Davenport A, Farrington K. Kt/V underestimates the hemodialysis dose in women and small men. Kidney Int. 2008;74:348–355
  5. Vanholder R, De Smet R, Glorieux G, et al. European Uremic Toxin Work Group (EUTox) Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int. 2003;63:1934–1943
  6. Pickett TM, Cruickshank A, Greenwood RN, Taube D, Davenport A, Farrington K. Membrane flux not biocompatibility determines beta-2-microglobulin levels in hemodialysis patients. Blood Purif. 2002;20:161–166
  7. Ward RA, Greene T, Hartmann B, Samtleben W. Resistance to intercompartmental mass transfer limits β2-microglobulin removal by post-dilution hemodiafiltration. Kidney Int. 2006;69:1431–1437
  8. Cheung AK, Rocco MV, Yan G, et al. HEMO Study Group Serum β2-microglobulin levels predict mortality in dialysis patients: Results of the HEMO study. J Am Soc Nephrol. 2006;17:546–555
  9. Locatelli F, Manzoni C, Di Filippo S. The importance of convective transport. Kidney Int Suppl. 2002;80:S115–S120
  10. Canaud B, Bragg-Gresham JL, Marshall MR, et al. Patients receiving hemodiafiltration or hemofiltration have lower mortality risk than patients receiving hemodialysis without replacement fluid (HD) in Europe: The Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol. 2003;14:31A;(abstr)
  11. Jirka T, Cesare S, Di Benedetto A, Perera Chang M, Ponce P, Richards N. The impact of on-line haemodiafiltration (HDF) on patient survival: Results from a large network database. Nephrol Dial Transplant. 2005;20(suppl 5):S18–S19
  12. Raj DSC, Ouwendyk M, Francoeur R, Pierratos A. β2-Microglobulin kinetics in nocturnal haemodialysis. Nephrol Dial Transplant. 2000;15:58–64
  13. Leypoldt JK. Kinetics of β2-microglobulin and phosphate during hemodialysis: Effects of treatment frequency and duration. Semin Dial. 2005;18:401–408
  14. Sugisaki H, Onohara M, Kunitomo T. Dynamic behavior of plasma phosphate in chronic dialysis patients. Trans Am Soc Artif Intern Organs. 1982;28:302–307
  15. Spalding EM, Chamney PW, Farrington K. Phosphate kinetics during hemodialysis: Evidence for biphasic regulation. Kidney Int. 2001;61:655–657
  16. Minutolo R, Bellizzi V, Cioffi M, et al. Postdialytic rebound of serum phosphorus: Pathogenetic and clinical insights. J Am Soc Nephrol. 2002;13:1046–1054
  17. Pieratos A, Owendyk M, Francoeur R, et al. Nocturnal hemodialysis: Three-year experience. J Am Soc Nephrol. 1998;9:859–868
  18. Toussaint N, Boddington J, Simmonds R, Waldron C, Somerville C, Agar J. Calcium phosphate metabolism and bone mineral density with nocturnal hemodialysis. Hemodial Int. 2006;10:280–286
  19. Gura V, Beizai M, Ezon C, Polaschegg HD. The wearable artificial kidney (WAK). Contrib Nephrol. 2005;149:325–333
  20. Gura V, Beizai M, Ezon C. CRRT for CHF; The wearable continuous ultrafiltration system. ASAIO J. 2006;52:59–61
  21. Gura V, Ronco C, Nalesso F, et al. A wearable hemofilter: First human study of slow continuous ambulatory ultrafiltration. Kidney Int. 2008;74:497–502
  22. Davenport A, Gura V, Ronco C, Beizai M, Ezon C, Rambod E. A wearable haemodialysis device for patients with end-stage renal failure: A pilot study. Lancet. 2007;370:2005–2010
  23. Davenport A. Anticoagulation options for intermittent haemodialysis. Minerva Urol Nefrol. 2006;58:171–180
  24. Gura V, Beizai M, Ezon C, Snukal R, Rambod E. The wearable artificial kidney (WAK) removes beta2-microglobulins (B2M). J Am Soc Nephrol. 2006;17:723A–724A(abstr)
  25. Davenport A, Will EJ, Davison AM. Effect of the direction of dialysate flow on the efficiency of continuous arteriovenous haemodialysis. Blood Purif. 1990;8:329–336
  26. Brunet S, Leblanc M, Geadah D, Parent D, Courteau S, Cardinal J. Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis. 1999;34:486–492
  27. Emmett M. A comparison of clinically useful phosphorus binders for patients with chronic kidney failure. Kidney Int Suppl. 2004;60:S25–S32
  28. Morey B, Walker R, Davenport A. More dietetic time, better outcome? (A randomized prospective study investigating the effect of more dietetic time on phosphate control in end-stage kidney failure haemodialysis patients). Nephron Clin Pract. 2008;109:c173–c180
  29. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998;31:607–617
  30. Ayus JC, Mizani MR, Achinger SG, Thadhani R, Go AS, Lee S. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: A prospective, controlled study. J Am Soc Nephrol. 2005;16:2778–2788
  31. Mucsi I, Hercz G, Uldall R, Ouwendyk M, Francoeur R, Pierratos A. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int. 1998;53:1399–1404
  32. Davenport A, Will EJ, Davison AM. Effect of renal replacement therapy on patients with combined acute renal and fulminant hepatic failure. Kidney Int Suppl. 1993;41:S245–S251
  33. Coburn JW, Hartenbower DL, Brickman AS, et al. Intestinal absorption of calcium, magnesium and phosphorus in chronic renal insufficiency. In:  David DS editors. Calcium and Metabolism in Renal Failure and Nephrolithiasis. New York, NY: Wiley; 1977;p. 77–109
  34. Ramirez JA, Emmett M, White MG. The absorption of dietary phosphorus and calcium in hemodialysis patients. Kidney Int. 1986;30:753–759
  35. Davenport A. The coagulation system in the critically ill patient with acute renal failure and the effect of an extracorporeal circuit. Am J Kidney Dis. 1997;30(suppl 4):S20–S27
  36. Davenport A. The management of heparin induced thrombocytopenia during renal replacement therapy. Hemodial Int. 2001;3:81–85

 Originally published online as doi: 10.1053/j.ajkd.2009.02.006 on April 20, 2009.

 Trial registration: ClinicalTrials.gov; study number: NCT00454974.

PII: S0272-6386(09)00433-8

doi: 10.1053/j.ajkd.2009.02.006

American Journal of Kidney Diseases
Volume 54, Issue 1 , Pages 104-111 , July 2009

Article Tools

* Image Usage & Resolution